When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RHHBY - Roche Looks To Expand MabThera's Reach In Wake Of Reduced Herceptin Sales
Roche Holding Ltd ADR
Roche (RHHBY) announced that it had received European approval for MabThera to treat patients with pemphigus vulgaris ((PV)). This approval is a good one, because it will help expand the market opportunity for MabThera. Especially, since the company had already received approval for the drug in the United States back in June of 2018. Roche needs as many approvals as it can get for this drug, because its mainstay drug Herceptin is facing and will face competition in terms of biosimilars.